References
- Harpe C, Stoudemire A. Aetiology and treatment of neuroleptic malignant syndrome. Med Toxicol 1987: 2(3): 166–76
- Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985: 142(10): 1137–45
- Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989: 149(9): 1927–31
- D'Angio RD. Neuroleptic malignant syndrome. Drug Info Bull 1986: 12(3): 10–1
- Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignandike syndrome due to levodopa therapy withdrawal. JAMA 1985: 254(19): 2792–5
- Gibb WR, Griffith DN. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J 1986: 62(723): 59–60
- Figa-Talamanca L, Gualandi C, Di Meo L, et al. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology 1985: 35(2): 258–61
- Hirschorn KA, Greenberg HS. Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome: a case report. Clin Neuropharmacol 1988: 11(3): 278–81
- Toru M, Matsuda O, Makiguchi K, et al. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981: 169(5): 324–7
- Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980: 41(3): 79–83
- Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986: 73(4): 337–47
- Kurlan R, Hamill R, Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol 1984: 7(2): 109–20